Form D · Pharmaceuticals
Triton Therapeutics, Inc.
Stamford, CT · CIK 0002088152
Offering snapshot reported Oct 23, 2025 · SEC filing
- Reported sold
- $36.4M Offering amount: $36.4M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 17, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 23, 2025 | Initial | $36,355,769 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-561892
Source: Form D, filed Oct 23, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Fonteyne | Director, Executive |
| Elena Grigoryeva | Director |
| Annie Mitsak | Director |
| Timothy Shannon | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
700 Fairfield Avenue, Suite 1
Stamford, CT, 06902
Phone: 203-482-3123
Stamford, CT, 06902
Phone: 203-482-3123